NEW YORK - IN8bio, Inc. (NASDAQ:INAB), a company specializing in gamma-delta T cell therapies, has reported promising preliminary results from its Phase 1 study of INB-200, a treatment for newly diagnosed glioblastoma multiforme (GBM).
The study data, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting on Saturday, indicated that 92% of patients treated with INB-200 surpassed the median progression-free survival (PFS) of seven months, which is the benchmark set by the current standard-of-care regimen.
The standard treatment for GBM typically includes surgery followed by chemoradiation and maintenance therapy with temozolomide (TMZ), known as the Stupp regimen. However, the novel approach using INB-200, in combination with TMZ, has shown a median PFS of over seven months in a cohort of patients, with follow-up data indicating a median of 11.7 months. Notably, one patient from the study has remained alive and progression-free for nearly three years.
The Phase 1 study evaluated the addition of INB-200 to the standard maintenance therapy. INB-200 consists of genetically modified, chemotherapy-resistant gamma-delta T cells. Thirteen patients were enrolled and treated across three different dosing regimens, with the most extensive regimen involving six doses.
Dr. Burt Nabors, from the Heersink School of Medicine at the University of Alabama at Birmingham, highlighted the potential impact of INB-200 in extending PFS for GBM patients. The trial's safety profile was also noted, with no reported cell therapy-related toxicities or serious adverse events across all dose cohorts.
Radiographic evaluations conducted as part of the study have shown treatment effects such as resolution of mid-line shift and changes in MRI enhancement in some patients. Additionally, the persistence of gamma-delta T cells in a relapsed tumor was documented in one case, suggesting the durability of the treatment.
IN8bio is currently advancing to a Phase 2 trial with INB-400, a related therapy, and continues to monitor long-term outcomes from the Phase 1 study. The company's focus on developing gamma-delta T cell therapies for solid and liquid tumors represents a burgeoning field in cancer treatment.
This article is based on a press release statement from IN8bio, Inc. and does not include independent verification of the data. The company has a range of preclinical and clinical programs targeting various cancers, with ongoing trials in both solid and hematological malignancies.
InvestingPro Insights
As IN8bio, Inc. (NASDAQ:INAB) showcases its promising preliminary results for its innovative treatment, INB-200, investors and stakeholders are closely monitoring the company's financial health and stock performance. According to InvestingPro data, IN8bio holds a market capitalization of $52.51 million, reflecting the market's current valuation of the company.
The company's financial strength is further highlighted by a notable InvestingPro Tip: IN8bio holds more cash than debt on its balance sheet, which could provide the flexibility needed to fund ongoing research and development efforts. Moreover, IN8bio has demonstrated a significant return over the last week, with a 17.82% price total return, and an impressive 40.75% return over the last six months, signaling a robust investor confidence in the short term.
Despite these encouraging signs, challenges remain. The company has not been profitable over the last twelve months, and analysts have revised their earnings downwards for the upcoming period. The company's P/E Ratio stands at -1.34, with an adjusted P/E Ratio for the last twelve months as of Q1 2024 at -1.69, indicating that it is not currently generating positive earnings. These financial metrics underscore the speculative nature of investing in biotech firms like IN8bio, where the potential for future profitability is often weighed against the current earnings picture.
For investors seeking a deeper analysis, there are 10 additional InvestingPro Tips available, which could provide further insights into IN8bio's financial stability and growth prospects. Interested readers can take advantage of the special offer using coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, unlocking access to these valuable tips.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.